Skip to content
Search

Latest Stories

Amanda Pritchard appointed chief executive of Guy's and St Thomas'

She will rejoin the organisation after six years to head one of the country's largest NHS Trusts.

Amanda Pritchard appointed chief executive of Guy's and St Thomas'

Amanda Pritchard appointed chief executive of Guy's and St Thomas'

Amanda Pritchard, who is set to step down as NHS England chief in April, has been appointed as the next chief executive of Guy’s and St Thomas’ NHS Foundation Trust.

Pritchard previously led the Trust from October 2015 to August 2019 before moving to NHS England, where she later became its first female chief executive in August 2021.


The Trust confirmed her appointment on Monday (17 March) following a competitive recruitment process and approval by the Council of Governors.

She will succeed Professor Ian Abbs, who announced in January that he will stand down in 2025.

Returning to an expanded organisation following its merger with Royal Brompton and Harefield Hospitals in 2021, Pritchard will lead one of the largest NHS Trusts in the country.

Charles Alexander, chairman of Guy’s and St Thomas’, praised Pritchard’s outstanding vision for the Trust.

He said: "We were extremely impressed by Amanda’s enthusiasm, energy and commitment to the future success of Guy’s and St Thomas’.

“She will return to a very different organisation from the one that she left 6 years ago and clearly demonstrated her vision and support for our ambitious plans, combined with the need to lead transformational change at pace.”

“We and our local healthcare and academic partners are fortunate that we will be able to benefit from the significant experience that Amanda has acquired during her time at NHS England as she returns to a role in frontline healthcare delivery.”

Expressing her pride in rejoining the Trust, Pritchard acknowledged the changes since her departure in 2019.

“It is an honour to be appointed to the role of Chief Executive at Guy’s and St Thomas’ – the organisation is now very different to the one I left in 2019 and I am delighted and proud to return to lead it,” she said.

“Guy’s and St Thomas’ is one of the country’s leading providers and I am very much looking forward to connecting with colleagues old and new as, together, we work to improve and transform the experiences of our staff and patients,” she added.

Pritchard first joined Guy’s and St Thomas’ as chief operating officer in 2012. Before that, she held several senior positions at Chelsea and Westminster NHS Foundation Trust and worked in the Prime Minister’s Delivery Unit.


More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less